Pediatric Blood & Cancer · 20 Nov 2026
Multimodality Care and Survival in Adolescents and Young Adults With Metastatic Non‐Rhabdomyosarcoma Soft Tissue Sarcoma in California
Elysia Alvarezh-index 18, Renata Abrahao, Ann Brunson, Qian Li, Sheri L. Spunt, Aaron Weiss, Marcio Malogolowkin, Janai Carr‐Ascher, Morgan Darrow, R. Lor Randall, Theresa H. M. Keeganh-index 17
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
ABSTRACT Background Approximately 20% of adolescents and young adults (AYA: ages 15–39) with non‐rhabdomyosarcoma soft tissue sarcoma (NRSTS) are diagnosed with metastatic disease, which has a dismal prognosis. Optimal care is critical to improve outcomes, but there is no consensus on the best management approach. We sought to evaluate multimodality care (MMC) and survival among AYAs with metastatic NRSTS. Methods We identified AYAs diagnosed during 2004–2022 with metastatic NRSTS in the California Cancer Registry. We defined MMC as first‐line treatment receipt of surgery, chemotherapy, and radiation per the Children's Oncology Group ARST0332 protocol. We used multivariable logistic regression to evaluate associations of sociodemographic and clinical factors with receipt of MMC, and multivariable Cox proportional hazards regression to examine the impact of MMC on overall survival. Results Of the 726 AYAs with metastatic NRSTS, 14% received MMC. A larger proportion of patients 15–25 years old who were treated by pediatric (vs. medical) oncologists received chemotherapy (96% vs. 75%), radiation (53% vs. 34%), and chemoradiation (51% vs. 25%). Older age (>21 years) was associated with decreased odds of receiving MMC. In patients ages 15–25, treatment by a pediatric (vs. medical) oncologist was associated with higher odds of receiving MMC (odds ratio [OR] = 3.4, 95% confidence interval [CI]: 1.33–8.72). Median overall survival was longer for patients receiving MMC (2.1 vs. 1.1 years), although associations did not remain statistically significant in the multivariable‐adjusted model (HR = 0.89, CI = 0.68–1.16). Receiving all care at a specialized cancer center was associated with improved overall survival (HR = 0.63, CI = 0.49–0.81). Conclusion We found that only 14% of AYAs with metastatic NRSTS received MMC, which was impacted by age at diagnosis and physician specialty. Future research should investigate decision‐making in patients with metastatic NRSTS and their providers, and its impact on outcomes.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Elysia Alvarez has the highest h-index among the authors (18).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (18)
What it cites, from open citation data, with Crossref's record of each.